MannKind Corporation (NASDAQ:MNKD) Given Average Rating of “Moderate Buy” by Analysts

MannKind Corporation (NASDAQ:MNKD) has been given a consensus rating of “Moderate Buy” by the nine research firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.2143.

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded MannKind from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. Zacks Research cut shares of MannKind from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 10th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $3.50 price objective (down from $7.50) on shares of MannKind in a research report on Friday. Finally, Wells Fargo & Company cut their target price on shares of MannKind from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Friday.

MannKind Stock Performance

NASDAQ MNKD opened at $3.28 on Friday. The firm’s 50 day moving average price is $5.55 and its two-hundred day moving average price is $5.36. MannKind has a twelve month low of $2.93 and a twelve month high of $6.51. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 164.08 and a beta of 0.84.

MannKind (NASDAQ:MNKD) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a negative return on equity of 11.12% and a net margin of 1.68%.The business had revenue of $111.96 million during the quarter, compared to analyst estimates of $99.85 million. During the same period last year, the business earned $0.03 EPS. The business’s quarterly revenue was up 45.8% on a year-over-year basis. On average, research analysts forecast that MannKind will post 0.1 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Michael Castagna sold 107,920 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $5.57, for a total transaction of $601,114.40. Following the completion of the sale, the chief executive officer directly owned 2,504,792 shares in the company, valued at approximately $13,951,691.44. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of MannKind stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the sale, the insider directly owned 985,007 shares of the company’s stock, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 262,846 shares of company stock worth $1,546,840 over the last ninety days. 2.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On MannKind

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its position in MannKind by 108.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 2,927 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of MannKind in the 4th quarter valued at $45,000. Huntington National Bank boosted its holdings in MannKind by 420.0% in the fourth quarter. Huntington National Bank now owns 10,400 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 8,400 shares in the last quarter. Burkett Financial Services LLC acquired a new position in MannKind during the fourth quarter worth $59,000. Finally, Laurel Wealth Advisors LLC bought a new position in MannKind during the fourth quarter valued at about $60,000. Institutional investors own 49.55% of the company’s stock.

Key Stories Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.